Ipamorelin
A selective ghrelin-receptor (GHSR) agonist that elicits GH release with minimal prolactin or cortisol elevation.
How it works
Binds GHSR-1a in the pituitary, triggering GH release; clean selectivity profile vs older GHRPs.
Reported benefits
- Lean-mass and recovery support when stacked with a GHRH analogue
- Improved sleep depth in some reports
- Lower side-effect burden than hexarelin or GHRP-6
Dosage & administration
Research range: 100-300 mcg subcutaneously 1-3x daily, frequently paired with CJC 1295 no-DAC.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Ipamorelin, the first selective GH secretagogue
European Journal of Endocrinology · 1998
Demonstrated GH release without prolactin/cortisol increase in healthy volunteers.
Safety & warnings
- Possible hunger spikes (ghrelin receptor)
- Mild headache, transient flushing
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
IP5
Box of 10 · $114
Single vial · $228
10 mg
IP10
Box of 10 · $216
Single vial · $432
Related guides
BPC 157
A pentadecapeptide derived from human gastric juice with broad regenerative effects in pre-clinical models.
TB500 (Thymosin B4 Acetate)
A synthetic fragment of thymosin β-4 that promotes cell migration, angiogenesis, and tissue repair.
BPC + TB Blend
Combined BPC 157 and TB500 blend used in recovery protocols to overlap angiogenic and cytoskeletal effects.